Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.

Schulze-Koops, Hendrik; Krueger, Klaus; Vallbracht, Inka; Hasseli, Rebecca; Skapenko, Alla

Schulze-Koops, Hendrik; Krueger, Klaus; Vallbracht, Inka; Hasseli, Rebecca; Skapenko, Alla.

Afiliação

Schulze-Koops H; Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilans University Munich, Munich, Germany hendrik.schulze-koops@med.uni-muenchen.de.
Krueger K; Praxiszentrum St. Bonifatius, Munich, Germany.
Vallbracht I; Department of Rheumatology, Clinical Immunology and Osteology, München Klinik Bogenhausen, Munich, Germany.
Hasseli R; Department of Rheumatology and Clinical Immunology, Justus-Liebig-University Giessen, Giessen, Germany.
Skapenko A; Division of Rheumatology and Clinical Immunology, Deparmtent of Medicine IV, Ludwig Maximilians University Munich, Munich, Germany.

Ann Rheum Dis ; 80(5): e67, 2021 05.

Article em En | MEDLINE | ID: mdl-32591357

Assuntos

Antirreumáticos; Artrite Reumatoide; COVID-19; Antirreumáticos/efeitos adversos; Artrite Reumatoide/tratamento farmacológico; Humanos; Rituximab/uso terapêutico; SARS-CoV-2

Palavras-chave

B-Lymphocytes; arthritis, rheumatoid; rituximab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos / COVID-19 Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google